Oragenics, Inc. OGEN

Company Overview

Oragenics, Inc. is a U.S.-based biotechnology company focused on the development of intranasal pharmaceutical products for neurological disorders and infectious disease-related applications. The company operates primarily within the biopharmaceutical and specialty therapeutics industries, with an emphasis on proprietary drug delivery technologies designed to improve administration efficiency and patient accessibility. Oragenics has historically explored vaccine technologies and lantibiotic-based antimicrobial programs, though its more recent strategic focus has centered on neurological therapeutics delivered through intranasal platforms.

The company’s principal business activities have included development-stage therapeutics targeting concussion, traumatic brain injury, and related neurological conditions. A key revenue and value driver has been its proprietary powder formulation and intranasal delivery platform, which the company believes may enable rapid drug absorption and non-invasive administration. Oragenics was founded in 1996 and evolved from early-stage infectious disease and oral health biotechnology programs into a more focused neurology-oriented development company through portfolio restructuring, licensing activity, and changes in research priorities.